<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01320709</url>
  </required_header>
  <id_info>
    <org_study_id>14835</org_study_id>
    <secondary_id>2010-021195-28</secondary_id>
    <nct_id>NCT01320709</nct_id>
  </id_info>
  <brief_title>Effect of Piroxicam on Ovulation</brief_title>
  <official_title>Single-center, Randomized, Placebo-controlled, Double-blind, Parallel Group Study to Evaluate Whether a Single-dose of Either 20 mg Piroxicam, 40 mg Piroxicam or 80 mg Piroxicam Shows an Effect on Ovulation After the Onset of LH Surge Compared to Placebo in Healthy Young Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study the effect of piroxicam on the ovulation will be evaluated. Therefore piroxicam
      will be administered as a single-dose after onset of LH surge (luteinizing hormone, hormone
      which triggers ovulation).

      Additionally blood levels of endogenous hormones (hormones produced by your body) will be
      measured and transvaginal ultrasound examinations will be conducted at regular intervals. In
      addition the concentration of piroxicam in blood will be determined in regular intervals.

      With regards to the tolerability of the study drug subjects will be asked regularly how they
      feel.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of piroxicam on ovulation (delay or inhibition) when given after the onset of LH surge</measure>
    <time_frame>after 2 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>course of follicle sizes</measure>
    <time_frame>after 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>course of gonadotropins (follicle-stimulating hormone [FSH], LH) and ovarian steroids (estradiol [E2], progesterone)</measure>
    <time_frame>after 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration-times courses of piroxicam</measure>
    <time_frame>after 2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Contraception, Postcoital</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Piroxicam ( BAYl1902)</intervention_name>
    <description>Single dose of 20 mg piroxicam (i.e., 1 piroxicam capsule + 3 placebo capsule)</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Piroxicam ( BAYl1902)</intervention_name>
    <description>Single dose of 40 mg piroxicam (i.e., 2 piroxicam capsules + 2 placebo capsule)</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single dose of placebo (i.e., 4 placebo capsules)</description>
    <arm_group_label>Arm 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Piroxicam ( BAYl1902)</intervention_name>
    <description>Single dose of 80 mg piroxicam (i.e., 4 piroxicam capsules)</description>
    <arm_group_label>Arm 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent available before any study specific tests or procedures are
             performed

          -  Healthy female subject

          -  Age: 18 to 35 years (inclusive) at the first screening visit

          -  Body mass index (BMI ): 18-30 kg/mÂ² (inclusive) at the first screening visit

          -  Confirmation of the subject's health insurance coverage prior to the first screening
             visit

          -  Willingness to use non-hormonal methods of contraception during the study

          -  Ability to understand and follow study-related instructions

          -  Adequate venous access

        Exclusion Criteria:

          -  Incompletely cured pre-existing diseases for which it can be assumed that the
             absorption, distribution, metabolism, elimination, and effects of the study drugs will
             not be normal

          -  Hypersensitivity to the active substance or skin reactions (irrespective of severity)
             to piroxicam, non-steroidal anti-inflammatory drugs or other medicinal products in the
             past

          -  History or presence of inflammatory diseases of the gastrointestinal tract,
             gastrointestinal bleeding, ulcers or perforation

          -  Regular intake of medication other than hormonal contraceptives

          -  Clinically relevant findings in the gynecological examination including transvaginal
             ultrasound (TVU)

          -  Clinically relevant findings in the physical examination, especially signs of bleeding
             diathesis or heart failure

          -  Time point &quot;onset of LH surge&quot; in the pre-treatment cycle not determinable

          -  Time point &quot;ovulation&quot; in the pre-treatment cycle not determinable

          -  Lacking suitability for frequent TVU examinations

          -  History or presence of suffering from hay fever
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <link>
    <url>http://www.bayerpharma.com/en/research-and-development/clinical-trials/trial-finder/index.php</url>
    <description>Click here and search for websynopsis results provided by Bayer</description>
  </link>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2011</study_first_submitted>
  <study_first_submitted_qc>March 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2011</study_first_posted>
  <last_update_submitted>July 9, 2015</last_update_submitted>
  <last_update_submitted_qc>July 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Emergency contraception</keyword>
  <keyword>Contraception</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Piroxicam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

